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Abstract
Background: Aberrant DNA methylation has been identified as a key molecular event regulating the pathogenesis of
myelodysplastic syndromes (MDS); myeloid neoplasms with an inherent risk of transformation to acute myeloid leukemia
(AML). Based on the above findings, DNA hypomethylating agents (HMA) have been widely used to treat AML and MDS,
especially in elderly patients and in those who are not eligible for allogeneic stem cell transplantation (SCT). Our goal
was to determine if there is any therapeutic advantage of HMA vs. conventional care regimens (CCR) and indirectly
compare the efficacy of azacitidine and decitabine in this patient population.
Methods: Eligible studies were limited to randomized controlled trials comparing HMA to CCR in adult patients with
AML or MDS.
Results: Overall survival (OS) rate was 33.2 vs. 21.4 % (RR 0.83, 95 % CI 0.71–0.98) and overall response rate (ORR) 23.7 vs.
13.4 % (RR 0.87, 95 % CI 0.81–0.93) for HMA and CCR, respectively. In subgroup analyses, only azacitidine treatment
showed OS improvement (RR 0.75, 95 % CI 0.64–0.98) and not decitabine. Cytogenetic risk or bone marrow blast count
did not have independent prognostic impact.
Conclusion: Collectively, these results demonstrate that HMA have superior outcomes compared to CCR and suggest
that azacitidine in comparison to decitabine, may be more effective.
Keywords: AML, MDS, DNA hypomethylating agents, Epigenetics
Background
Myelodysplastic syndromes (MDS) are clonal hematopoietic
stem cell disorders characterized by peripheral blood cytope-
nias, hypercellular bone marrows, and an inherent predis-
position to transform to acute myeloid leukemia (AML) [1].
MDS are commonly associated with aging (age-related
acquisition of genomic and epigenetic changes), environ-
mental carcinogens, chemotherapy, and radiation exposure
(therapy-related MDS) [2]. AML, an aggressive stem cell
malignancy, with an annual incidence of 18,860 cases in the
USA in 2014 [3], is characterized by ≥20 % bone marrow
(BM) blasts and very poor outcomes with chemotherapy [4].
Although allogeneic stem cell transplantation (SCT) is the
only curative treatment for high risk MDS and AML [5, 6],
many patients are not eligible for transplantation due to
advanced age, associated co-morbidities, and a limited donor
pool [7]. Thus, there is an urgent need to develop new
therapeutic approaches for these patients.
In the last decade, attention has turned to epigenetic
changes in MDS/AML, especially aberrant DNA methy-
lation, a molecular process playing a role in the regula-
tion and expression of tumor suppressor genes and
oncogenes, promoting dysplasia and blast transform-
ation [8, 9]. These epigenetic modifications are distin-
guished from genetic mutations by their reversibility,
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making them potential therapeutic targets. Accordingly,
the clinical and biological efficacy of hypomethylating
agents (HMA) have been demonstrated in several in
vitro/in vivo studies and clinical trials [8, 10–13]. Des-
pite the promising initial treatment responses, the sur-
vival outcome data with HMA have been inconsistent.
Here, we provide a systematic review and pooled ana-
lysis of randomized clinical trials (RCT) comparing
the outcomes of HMA vs. conventional care regimens
(CCR) in patients with AML or MDS. CCR include
best supportive care (BSC), intensive chemotherapy
(IC), and low dose cytarabine (LDAC).
Materials and methods
Study selection criteria
Eligible studies were (1) RCTs, (2) assessing adult pa-
tients age ≥18 years with (3) morphologically proven
diagnosis of AML or MDS with no previous allogeneic
SCT, (4) treated with either HMA (azacitidine or
decitabine) or CCR (BSC, LDAC or IC) in a setting of
first-line treatment, and (5) including OS and treatment
response outcomes. Trials were used only once in the
analysis using the most updated available data.
Data sources
Literature search and review of relevant articles were
limited to human studies. Key words included AML,
MDS, azacitidine, and decitabine (Additional file 1: Table
S1). Relevant studies were identified by searching
PubMed, EMBASE, and Cochrane Database of System-
atic Reviews up to October 2015. Additional relevant
abstracts from the American Society of Hematology,
the American Society of Clinical Oncology, and the
European Hematology Association were also included
into the literature search. A bibliography of identified
articles and additional literatures from relevant refer-
ences were further investigated manually to identify any
relevant trials.
Data extraction
Two reviewers (SY and NDV) independently extracted
data with a piloted extraction form. Any disagreement
was resolved by consensus with other co-authors after
review of full text.
Data items
The following information was extracted from individual
trial reports: publication year, inclusion/exclusion cri-
teria, sample size, median age, French-American-British
(FAB) and World Health Organization (WHO) classifi-
cation, BM blast count, cytogenetic risk categories,
supportive care regimens, median follow-up, OS, treat-
ment response, and mortality attributed to disease pro-
gression. Extracted from each study report were the
number of patients treated with HMA or CCR, the pro-
portion of patients with events (death, complete remis-
sion (CR), partial remission (PR)), subgroup data, hazard
ratio (HR), 95 % CI, and p values. The primary outcome
in this analysis was OS rate, and the secondary outcome
was ORR (defined as rate of CR or PR). Trials reported
outcomes with variable follow-up of 1–2 years; however,
data from all studies were analyzed together with an as-
sumption that median survival of AML patients without
intensive chemotherapy or allogeneic SCT is less than
2 years in high-risk AML and MDS patients.
Assessment of bias risk
We used the Cochrane Collaboration’s tool [14], which
evaluates random sequence generation, allocation con-
cealment, blinding, incomplete outcome data, selective
reporting, and other source of bias.
Statistical analysis
Statistical analyses were performed as described in a pre-
vious meta-analysis [15]. Briefly, the Cochrane Q statistic
was used to estimate statistical heterogeneity, and the I2
statistic was used to quantify inconsistency. The assump-
tion of homogeneity was considered invalid if p < 0.10
and treatment effects were calculated with a random
effects model. The funnel plot method was applied to as-
sess publication bias. A two-sided p ≤ 0.05 was consid-
ered statistically significant in the RR and HR analysis
without multiplicity correction. Pre-defined criteria in-
cluding experimental agents (azacitidine vs. decitabine),
cytogenetic risk, and BM blast count were used for the
subgroup analyses to explore heterogeneity and to iden-
tify subgroups with differential benefit from HMA treat-
ment (Table 2). RR and HR differences between
subgroups were evaluated by regression models. Analysis
calculations were performed using RevMan Version 5.3.
Results
Search results
Our initial literature search yielded a total 254 potential
abstracts (Fig. 1 and Additional file 1: Figure S1). Of this,
232 studies were excluded for being irrelevant to our
analysis including editorials, study protocols, and
commentaries. Total 22 articles were reviews in full text
for their eligibility. Additional nine single arm studies
[16–24] and two retrospective studies [25, 26] were ex-
cluded from the analysis, as was one study [27] with no
survival outcome report and five duplicate or ad hoc
studies [28–32]. With careful review of eligibility, a total
of five open label multicenter phase III RCTs (four pub-
lished articles [33–36] and one abstract [37]) were se-
lected for the current analysis. The characteristics of
these trials are summarized in Table 1 and Additional
file 1: Table S2.
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Patients
All trials included patients with morphologically con-
firmed AML or MDS and age of 18 years or greater. A
total of 1755 patients were included in the analysis. Of
these, 880 were treated with either azacitidine (n = 519)
or decitabine (n = 361) and 875 with CCR including BSC
(n = 384), LDAC (n = 422), and IC (n = 69) (Table 1). The
range of median ages of patients on the selected trials
was 68–75 years. Cytogenetic risk stratification was per-
formed following South West Oncology Group (SWOG)
[38] and International Prognostic Scoring System (IPSS)
[39] categorization of AML and MDS, respectively. The
number of patients with BM blast ≥30 %, oligoblastic
AML (BM blasts 20–30 %), de novo AML, and inter-
mediate/poor risk cytogenetic AML were 858, 366, 312,
and 1278, respectively (Additional file 1: Table S2). The
numbers of MDS patients with low and intermediate/
high IPSS risk categorization were 7 and 636, respect-
ively. Cytogenetic analysis was done on only 42 % of pa-
tients in one study [35], while additional studies [35, 37]
failed to report subgroup outcomes according to cytogen-
etic risk and BM blast count. Three studies [33, 35, 36] in-
cluded both AML and MDS patients and two studies
[34, 37] included AML only (by FAB classification).
Two trials [34, 37] included de novo AML patients
without separate outcome report between transformed/
secondary vs. de novo AML, and one of these studies
included 158 patients with AML with myelodysplastic-
related change (AML-MRC) [37]. Median follow-up was
reported in only two studies [33, 36]. Forty-nine (53 %)
CCR patients in one study [35] crossed over to the azaciti-
dine arm, while the remaining studies did not have cross-
over options.
RR of OS rate and ORR
The combined estimate demonstrated an association of
HMA treatment with significantly better OS rate of 33.2
vs. 21.4 % (RR 0.83, 95 % CI 0.71–0.98, p = 0.03) and
higher ORR of 23.7 vs. 13.4 % (RR 0.87, 95 % CI 0.81–0.93,
p = 0.0001) (Fig. 2). There was significant heterogeneity in
OS (I2 = 89 %, p < 0.00001) and ORR (I2 = 63 %, p = 0.03)
analyses across studies.
Subgroup analyses
Azacitidine treatment was associated with significantly
better OS compared to CCR (HR 0.67, 95 % CI 0.56–
0.79, p < 0.00001), while no statistically significant OS
benefit was observed in the decitabine treatment group
(HR 0.86, 95 % CI 0.73–1.02, p = 0.08) (Table 2), par-
tially explaining the heterogeneity in the OS analysis
(Additional file 1: Figure S2A). Both azacitidine (RR
0.87, 95 % CI 0.78–0.97, p = 0.01) and decitabine (RR
0.86, 95 % CI 0.76–0.98, p = 0.03) treatments showed a
higher ORR when each was compared to CCR with no
Fig. 1 Trial Selection Process for the Systematic Review
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Table 1 Characteristics of trials included in the analysis
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≥ 30%: 19 (10)
45 (24) 67 (35) 0 (0) 67 (35) BSC: 92 (100) 99 92 NR Azacitidine: 75 mg/m2/d
subcutaneous injection in 7 day









< 30%: 356 (99)
≥ 30%: 2 (1)
123 (34) 113 (32) 0 (0) 113 (32) BSC: 105 (59)
LDAC: 49 (27)
IC: 25 (14)
179 179 21.1 Azacitidine: 75 mg/m2/d
subcutaneous injection every 28
days for at least 6 cycles.
LDAC: 20 mg/m2/d
subcutaneous injection for 14 d,
every 28 days, at least 4 cycles.
IC: cytarabine 100-200 mg/m2/d
continuous intravenous infusion
for 7 days plus 3 days of either
intravenous daunorubicin 40-65
mg/m2/d or idarubicin 9-12 mg/
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≥ 30%: 2 (1)
75 (32) 77 (32) 0 (0) 77 (32) BSC: 114 (100) 119 114 30 Decitabine: 15 mg/m2 in 2
doses, intravenous infusion every
8h for 3 d. This treatment cycle
was repeated every 6 wks.






< 30%: 123 (25)
≥ 30%: 347 (72)
123 (25) 485 (100) 312 (64) 173 (36) BSC: 28 (12)
LDAC: 215 (88)
242 243 NR Decitabine: 20 mg/m2/d
intravenous infusion for 5 d. This
treatment cycle was repeated
every 4 wks.
LDAC: 20 mg/m2/d
subcutaneous injection for 10
consecutive days every 4 wks.
Dombret 2014
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≥ 30%: 488 (100)
0 (0) 488 (100) NR e NR e BSC: 45 (18)
LDAC: 158 (64)
IC: 44 (18)
241 247 NR Azacitidine: 75 mg/m2/d
subcutaneous for 7 d, 28 d cycle.
LDAC: 20 mg/m2 subcutaneous
injection twice a day for 10 days
with every 28 days cycle.
IC: standard 7 + 3 regimen
a FAB classification: RA (refractory anemia), RARS (refractory anemia with ring sideroblasts), RAEB (refractory anemia with excessive blasts), RAEB-t (RAEB in transformation with BM blast 21-30%)), CMMoL (chronic
myelomonocytic leukemia), AML (acute myeloid leukemia with BM blast more thatn 30%)
b Oligoblasatic AML: BM blast counts 20-30%
c De novo AML: the definition of de novo and secondary AML followed the revised recommendations of the International Working Group [58] (no clinical history of MDS, MPD or exposure to potential leukemogenic
treatment or agents) and followed WHO classification.
d Others: AML (n = 19), undefined leukemia (n = 1), undefined MDS (n = 1)
e This study included both de novo and secondary AML. Total 158 patients had AML with myelodysplastic related change (AML-MRC).









RR difference between both treatments relative to CCR
(p = 0.97) (Additional file 1: Figure S3). There was no
statistically significant association of OS with cytogen-
etic risk, BM blast count, and use of LDAC or IC
supplemental to BSC (Table 2 and Additional file 1:
Figure S2B-D). Additional subgroup analyses directly
comparing the OS rates of HMA and LDAC in AML
patients revealed no significant difference (21.8 vs.
12.1 %, RR 0.77, 95 % CI 0.52–1.16, p = 0.21) between
HMA and LDAC. Azacitidine treatment was associated
with significantly better OS rates compared to LDAC (RR
0.66, 95 % CI 0.49–0.87, p = 0.004); however, no significant
OS benefit over LDAC was seen in the decitabine sub-
group (RR 0.97, 95 % CI 0.92–1.02, p = 0.24) (Additional
file 1: Figure S4 and Table S4).
Bias analysis
All five trials were open-labeled RCT. Random sequence
generation and allocation concealment were performed
adequately in all studies. The adequacy of blinding was
Table 2 Subgroup analysis of overall survival from available data
Subgroup No. of studies OS HR
(95 % CI)d
Weight (%) Heterogeneity within subgroup
Criteria Characteristics I2 (%) p value
Experimental drug Azacitidinea 3 0.67 (0.56, 0.79) 48.3 0 0.38
Decitabine 2 0.86 (0.73, 1.02) 51.7 0 0.85
Subgroup difference p = 0.04*
Cytogenetics riskb Poor risk 3 0.75 (0.56, 1.00) 43.9 26 0.26
Intermediate risk 3 0.78 (0.40, 1.52) 37.0 65 0.06
Good risk 2 0.63 (0.42, 0.93) 19.0 0 0.64
Subgroup difference p = 0.75
BM blast countc More than 30 % 2 0.79 (0.68, 0.92) 48.9 0 0.32
Less than 30 % 3 0.82 (0.57, 1.18) 51.1 74 0.02
Subgroup difference p = 0.85
Conventional care regimens BSC only 2 0.76 (0.53, 1.10) 28.4 44 0.18
BSC and CTxe 3 0.73 (0.60, 0.90) 71.6 53 0.12
Subgroup difference p = 0.85
aOne study [25, 30] included only RAEB and RAEB-T for the HR analysis of OS
bTwo studies [30, 32] did not report subgroup survival outcome data according to cytogenetic risk
cOne study [30] did not report subgroup survival outcome data according to BM blast count (≥30 vs. <30 %)
dHR value was extracted from subgroup analysis data of individual trial
eCTx includes low dose cytarabine and intensive chemotherapy
*Statistically significant
Fig. 2 a Risk Ratio of the OS Rate. b Risk Ratio of the Overall Response Rate
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judged by whether treatment response was evaluated by a
third person who did not know the treatment group of
the patients. Only one study [34] performed blinded as-
sessment. Treatment response was assessed by unblinded
reviewers in one study [36], and blinding status was un-
clear in three studies [33, 35, 37]. The baseline demo-
graphic characteristics were balanced in all trials (Table 1
and Additional file 1: Table S2), and potential sources of
bias are described in Additional file 1: Table S3. OS and
treatment response analyses showed significant heterogen-
eity, largely attributable to the HMA agent. The observed
funnel plot asymmetry can be explained as a function of
experimental agents (Additional file 1: Figure S1).
Discussion
We performed a systematic review and pooled analysis
to compare the outcomes of HMA vs. CCR in patients
with AML and MDS. The combined analyses revealed
statistically significant OS and CR/PR benefit with HMA
therapy in comparison to CCR (Fig. 2). These results
confirm that HMA are reasonable therapeutic options
with survival advantage, especially for elderly and trans-
plant ineligible AML and MDS patients.
Aberrant DNA methylation has been suggested as a
dominant mechanism of MDS progression to AML,
and patients with MDS and AML have been shown to
have unique patterns and abundance of aberrant DNA
methylation compared to normal controls [40, 41], thus
representing a suitable therapeutic target. Azacitidine
(5-azacytidine) is metabolized into decitabine (5-aza-2′-
deoxycytidine), which forms a covalent protein-DNA
adduct, depleting intracellular methyl-transferase, lead-
ing to reversal of DNA hypermethylation on tumor
suppressor genes and induction of apoptosis [8, 10–13].
As such, DNA demethylation has been widely accepted
as the primary mechanism of cytotoxicity of HMA and
a previous study showed the association of CDKN2B
(that encodes p15INK4B) pre-treatment methylation level
with treatment response to azacitidine [42]. However,
interestingly, our subgroup analyses demonstrated an
association of OS benefit with azacitidine treatment,
but not with decitabine (Table 2), similar to a recent
retrospective study with AML patients that showed su-
perior outcomes with azacitidine therapy in comparison
to decitabine [25]. Furthermore, Fandy et al. showed
that reversal of methylation on four tumor suppressor
genes (p15INK4B, CDH-1, DAPK-1, and SOCS-1) had no
prognostic impact on clinical response to the combin-
ation treatment of azacitidine and entinostat (histone
deacetylase inhibitor) [43, 44]. Collectively, these results
indicate potential cytotoxic mechanisms that are inde-
pendent to DNA demethylation.
Both azacitidine and decitabine have been shown to
induce DNA damage and cell cycle arrest, however, to
different extents [45, 46], suggesting DNA damage as a
possible underlying mechanism of HMA-induced cyto-
toxicity. However, a similar degree of γ-H2AX expres-
sion was observed in both responders and non-
responders to azacitidine and entinostat treatment [43],
questioning the role of DNA damage. Further studies
are needed to define the role of DNA damage in the
cytotoxic effect of azacitidine. In a recent study, azaciti-
dine, but not decitabine, was shown to inhibit RNA
methylation on cytosine 38 and 48 of tRNAAsp, which
are target sites of DNMT2, and reduce the metabolic ac-
tivity in myeloid cell lines. This suggests that azacitidine
induces cytotoxicity via tRNA demethylation rather than
DNA although the detailed mechanisms still remain to
be answered. Also, Roulois et al. showed that the anti-
tumor effect of low-dose decitabine may depend on viral
mimicry, activating MDA5/MAVS/IRF7 RNA recognition
pathway in colorectal cancer-initiating cells [47], and its
role in myeloid neoplasms need further investigation.
Cytogenetic risk and BM blast counts are known to be in-
dependent prognostic factors in AML and MDS [39, 48–50].
However, in our study, subgroup analysis according to cyto-
genetic risk or BM blast count failed to show any RR differ-
ence (Table 2). Ninety-eight percent of MDS patients
enrolled in three trials [33, 35, 36] had intermediate or
high IPSS risk and two studies [34, 37] included only
AML patients whose prognosis is known to be dismal,
partially explaining why there was no subgroup difference.
Previously, LDAC has been shown to be associated
with higher response rates compared to supportive
care in elderly AML or MDS patients who were not
candidates for allogeneic SCT [51]. As such, three tri-
als [34, 36, 37] in the current analysis incorporated
LDAC as their control regimens. In a subgroup analysis
comparing HMA and LDAC in AML patients, the OS rate
in LDAC treatment group was significantly lower than
that of azacitidine, but not decitabine, suggesting that aza-
citidine may be a better therapeutic option in this patient
group (Additional file 1: Figure S4).
We recognize several limitations of the current ana-
lysis. First, there was significant heterogeneity in the OS
analysis (I2 = 89 %, p < 0.00001). The primary source of
heterogeneity was experimental agents as shown in
intra-subgroup homogeneity of three azacitidine trials
[35–37] (I2 = 0 %, p = 0.38) as well as two decitabine tri-
als [33, 34] (I2 = 0 %, p = 0.85). Although the proportion
of females in decitabine studies was relatively higher,
other demographic profiles or clinical parameters were
not substantially different from azacitidine trials (Table 1
and Additional file 1: Table S2). BM morphologic ab-
normalities were shown to be associated with worse
prognosis in de novo AML [52], and 32.4 % of patients
(n = 158) in one azacitidine study [37] had AML-MRC,
which may result in heterogeneity of treatment
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outcomes. However, a recent ad hoc study with AML-
MRC patients [53] showed significantly higher OS and
CR/CRi rates with azacitidine, similar to the original
data, rendering this possibility less likely. Second, in
one study [35], 53 % of patients who were initially ran-
domized to the CCR group crossed over to azacitidine
treatment. However, the outcomes of these patients were
analyzed along with the CCR group, which may underesti-
mate the efficacy of azacitidine. Third, inclusion of LDAC
and IC as BSC in three studies [34, 36, 37] may have con-
tributed to the heterogeneity, although the result from dir-
ect comparison of HMA and LDAC was not significantly
different from the original analysis (Additional file 1:
Figure S4). Fourth, schedule and administration method
and number of cycles of HMA used in the individual stud-
ies were different, potentially generating additional hetero-
geneity based on previous studies that showed better
treatment response with prolonged azacitidine treatment
[54] and lower bioavailability of subcutaneous azacitidine
compared to intravenous administration (AUC values
89 %) [55]. Lastly, the maximum tolerated dose (MTD) of
decitabine is known to be 1500–2000 mg/m2/course [56].
However, decitabine trials in our analysis used a 10–
25 mg/m2/day dose, which is significantly lower than the
MTD. This is based on previous phase I trial that focused
on pharmacodynamics rather than MTD [57]. The opti-
mal dose-schedule of decitabine, an S-phase specific
agent, needs be further investigated in the future study.
Our systematic review and pooled analyses have iden-
tified several areas that require further study. First, the
mechanisms of action of HMA and their therapeutic tar-
gets remain to be poorly defined. Inhibition of tRNA has
been suggested as a potential mechanism of azacitidine;
however, details supporting this need further elucidation.
Recently, activation of the MDA5/MAVS RNA recogni-
tion pathway was suggested as an underlying mechanism
of decitabine-induced cytotoxicity in colorectal cancer-
initiating cells, and its role in myeloid neoplasm requires
further elucidation. Second, the benefit of initial treat-
ment response with decitabine failed to translate into
OS improvement, supporting the possibility that the su-
perior OS with azacitidine may result from better disease
control, the mechanisms of which remain unknown. In
the same context, the optimal dose of decitabine still re-
mains to be defined. Third, potential biomarkers that
might have prognostic relevance with regards to response
to HMA therapy, including nucleoside transporters like
hCNT1 [58] and cytosine deaminase activity [59], also
need further study. Finally, a second-generation HMA has
been developed to reduce elimination of decitabine by
cytidine deaminase, thereby increasing the in vivo ex-
posure of decitabine. A recent phase I clinical trial
with SGI-110 (dinucleotide of decitabine and deoxy-
guanosine) demonstrated a comparable safety profile
to decitabine with a significantly longer half-life [60].
An ongoing phase II clinical trial (NCT01261312) will
hopefully provide more data in regards to the clinical
activity of second generation HMA.
Conclusions
In an analysis of prospective randomized controlled trials
in elderly patients with AML or MDS, HMA therapy was
associated with improved response rates and OS in com-
parison to CCR, which included BSC, LDAC, and IC. Fur-
ther analysis demonstrated that the observed survival
benefit was restricted to azacitidine therapy, suggesting
that azacitidine may be a better therapeutic option in
AML and MDS patients. Finally, we also conclude on the
need for additional mechanistic and epigenetic work to
better understand mechanisms of action of HMA, optimal
dosing strategies, and the identification of prognostic
markers and biomarkers to help better predict and moni-
tor response to therapy with these agents.
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